Amedisys/$AMED

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Amedisys

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Ticker

$AMED
Primary listing

Industry

Health Care Providers & Services

Employees

19,000

ISIN

US0234361089

Amedisys Metrics

BasicAdvanced
$3.2B
36.06
$2.72
0.89
-

What the Analysts think about Amedisys

Analyst ratings (Buy, Hold, Sell) for Amedisys stock.

Bulls say / Bears say

Amedisys reported adjusted earnings of $1.25 per share for Q1 2025, surpassing analyst expectations of $1.09, indicating strong financial performance. (tradingview.com)
The company has been recognized with 92 SHPBest™ Patient Satisfaction Awards in 2023, reflecting high patient satisfaction and quality of care. (stocktitan.net)
Amedisys' subsidiary, Contessa Health, was selected by CMS to participate in the GUIDE Model, potentially expanding its services and revenue streams. (stocktitan.net)
The U.S. Department of Justice filed a lawsuit to block UnitedHealth's $3.3 billion acquisition of Amedisys, citing concerns over reduced competition in the home health services market. (reuters.com)
Amedisys' net income for Q3 2024 decreased to $16.9 million from $26.0 million in the same quarter of 2023, indicating a decline in profitability. (stocktitan.net)
Analyst ratings have been downgraded, with Deutsche Bank lowering Amedisys to 'Hold' from 'Buy' and William Blair downgrading to 'Market Perform' from 'Outperform'. (marketscreener.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

Amedisys Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Amedisys Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMED

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs